Optimal duration of whole body hyperthermia when combined with cis-diaminne-1,1-cychlobutane dicarboxylate platinum (II) (carboplatin)

Anticancer Research

Volumn 17, Issue 3 C, 1997, Pages 1897-1901

  Kaneko, Tetsuya ^a,b   Sakaguchi, Yoshihisa ^a,c   Makino, Masato ^a,b   Matsuda, Hiroyuki ^a,c   Strebel, Frederick R ^a   Jenkins, Gay N ^a   Bull, Joan M C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b TOTTORI UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Carboplatin; Duration; Whole body hyperthermia

Indexed keywords

CARBOPLATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; FEMALE; FIBROSARCOMA; HYPERTHERMIC THERAPY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TIME; TUMOR GROWTH; WEIGHT REDUCTION;

ANIMALS; CARBOPLATIN; CELL DIVISION; COMBINED MODALITY THERAPY; ERYTHROCYTE COUNT; FEMALE; FIBROSARCOMA; HYPERTHERMIA, INDUCED; LEUKOCYTE COUNT; PLATELET COUNT; RATS; RATS, INBRED F344; TIME FACTORS;

EID: 0030808936     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Hahn GM: Theramal enhancement of actions of anticancer agents. In: Hyperthermia and Cancer (Hahn GM, ed). New York, Plenum Publishing Corp., 1982, pp 55-86.
2. Hahn GM: Potential for therapy of drugs and hyperthermia. Cancer Res 39:2264-2268, 1979.
3. Wondergem J, Bluger RE, Strebel FR, Newman RA, Travis EL, Stephen LC, and Bull JMC: Effect of cis-diamminedichloroplatinum (II) combined with whole body hyperthermia on renal injury. Cancer Res 48: 440-446, 1988.
4. Cohen JD and Robins HI: Hyperthermic enhancement of cisdiamine-1,1cyclobutane dicarboxylate platinum (II) cytotoxicity in human leukemia cells in vitro. Cancer Res 47: 4335-4337, 1987.
5. Cohen JD, Robins HI, Schmitt CL: Interactions of hyperthermia with carboplatin, cisplatin, and etoposide in human leukemia cells in vitro. Cancer Lett 44: 205-210, 1989.
6. Cohen JD, and Robins HI: Thermal enhancement of tetraplatin and carboplatin cytotoxicity in human leukemic cells in vitro. Int J Hyperthermia 6: 1013-1017, 1990.
7. Kusumoto T, Maehara Y, Baba H, Takahashi I, Kusumoto H, Ohno S, and Sugimachi K: Sequence dependence of hyperthermia of carboplatin-induced cytotoxicity and intracellular platinum accumulation in Hell cells. Br J Cancer 68: 259-263, 1993.
8. Tapazoglou E, Robins HI, Cohen J, Khatana A, Schmitt CL, Franken K, Corry P, and Sapareto SA: The enhancement of cytotoxicity of carboplatin (CBDCA) by whole body hyperthermia (WBH) in the murine AKR leukemia. Proc Am Assoc Cancer Res 29: 1342, 1988 (abstract).
9. Page RL, McEntee MC, Heinder GL, Riviere JE, and Thrall DE: Phase I evaluation of carboplatin at 37°C and 42°C in tumor-bering dogs. Proc Radiat Res Soc NAHG Abstract Bd-9, 1989.
10. Ohno S, Siddik ZH, Baba H, Stephens LC, Strebel FR, Wondergem J, Khokhar AR, and Bull JMC: Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Res 51: 2994-3000, 1991.
11. Siddik ZH, Boxall FE, and Harrap KR: Haematological toxicity of carboplatin in rats. Br J Cancer 55: 375-379, 1987.
12. Wondergem J, Strebel FR, Siddik ZH, Newman RA, and Bull JMC: The effect of anesthetics on cisplatin-induced toxicity at normal temperatures and during whole-body hyperthermia: the influence of NaCl concentration of the vehicle. Int J Hyperthermia 4: 643-654, 1988.
13. Robins HI, Steeves RA, Shecterle LM, Martin PA, Miller KA, Paliwal B, Neville AJ, and Dennis WH: Whole body Hyperthermia (41-42°C): A simple technique for unanesthetized mice. Med Phys 11: 833-839, 1984.
14. Robins HI, Dennis WH, Neville AJ, Shecterle LM, Martin PA, Grossman J, Davis TE, Neville SR, Gills WK, and Rusy BF: A nontoxic system for 41.8°C whole body hyperthermia: results of a phase I study using a radiant heat device. Cancer Res 45: 3937-3944, 1985.
15. Lord PF, Kapp DS, Hayes T, and Weshler Z: Production of systemic hyperthermia i n the rat. Eur J Clin Oncol 20: 1079-1085, 1984.
16. Ohno S, Strebel FR, Stephens LC, Siddik ZH, Baba H, Makino M, Khokhar AR and Bull JMC: Hematological loxicity of carboplatin and cisplatin with whole body hyperthermia in rats. Br J Cancer 68: 469-474, 1993.
17. Bull JMC, Cronau LH, Newman BM, Jabboury K, Allen SJ, Ohno S, Smith T, and Tonnesen AS: Chemotherapy resistant sarcoma treated with whole body hyperthermia (WBH) combined with 1-3-bis (2- chloroethyl)-l-nitrosourea (BCNU). Int J Hyperthermia 8: 297-304, 1992.
18. Van der Zee, Van Rhoon GC, Wike-Hooley JL, Faithfull NS, and Reinhold HS: Whole body hyperthermia in cancer therapy: a report of phase I-II study. Eur J cancer Clin Oncol 19: 1189-1200, 1983.
19. Parks LC, Minaberry D, Smith DP, and Neely WA: Treatment of far- advanced bronchologenic carcinoma by extracorporeally induced systemic hyperthermia. J Thorac Cardiovasc Surg 78: 883-892, 1979.
20. Larkin LM, Edwards WS, Smith DE, and Clark PJ: Systemic thermotherapy: description of a method and physiologic tolerance in clinical subjects. Cancer 40: 3155-3159, 1977.
21. Robinsons HI, Cohen JD, Schmitt CL, Tusch KD, Feierabend C, Arzoomanian RZ, Alberti D, d'Oleire F, Longo W, Heiss C, Rushing D, Love R, and Shriggs D: Phase I clinical trial and carboplatin and 41.8°C whole-body hyperthermia in cancer patients. J Clin Oncol 11: 1787-1794, 1993.
22. Egorin MJ, Van Echo DA, Tipping SJ, Olman BA, Whitacre MY, Thompson BW, and Aisner J: Pharmacokinetics and dosage reduction of cisdiammine (1,1-cyclobutane dicarboxylate) platinum in patients with impaired renal function. Cancer Res 44: 5432-5438, 1984.
23. Hahn GM, and Stande DP: Cylotoxic effects of hyperthermia and adriamycin on Chinese hamster cells. J Natl Cancer Invest 37: 1063- 1007, 1476.
24. Myen RE, Corry PM, Fletcher SE, and Demetriades M: Thermal enhancement of DNA strand breakage in mammalian cells treated with bleomycin in rats. Int J Radiat Oncol Bio Phys 5: 1487-1489, 1979.
25. Myen RE, Corry PM, Fletcher SE, and Demetriades M: Thermal enhancement of DNA damage in mammalian cells treated with cisdiammine dichloroplatinum (II). Cancer Res 40: 1136-1139, 1980.
26. Siddik ZH, Newell DR, Boxall FE, and Harrap KR: The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 36: 1925-1932, 1987.
27. Siddik ZH, Wondergem J, Strebel FR, Baba H, Alonso M, Burditt T, Khokhar AR, and Bull JM: Plasma clearances and tissue levels of cisplatin and carboplatin in rats receiving whole body hyperthermia. Proc Am Assoc Cancer Res 31: 392, 1990.
28. Urano M: Kinetics of thermotolerance in normal and tumor tissue: A review. Cancer Res 46: 474-482, 1986.
29. Makino M, Maeta M, Kaibara N, Sakaguchi Y, and Bull JMC: Optimal duration of whole body hyperthermia (WBH) when combined with cis-diamminechloroplatinum (II) (DDP). The 16th international symposium oncological hyperthermia. Program/Abstract: p75, B-441, 1993.
30. Sakaguchi Y, Makino M, Kaneko T, Stephens LC, Strebel FR, Danhauser LL, Jenkins GN, and Bull JMC: Therapeutic efficacy of long duration low temperature whole body hyperthermia when combined with tumor necrosis factor and carboplatin in rats. Cancer Res 54: 2223-2227, 1994.